

# Bulletin:

# Cheplapharm's Proposed New Issuance Will Not Affect Leverage Materially

September 18, 2023

This report does not constitute a rating action.

PARIS (S&P Global Ratings) Sept. 18, 2023--Pharmaceutical company Cheplapharm Arzneimittel GmbH's (Cheplapharm's; B+/Stable/--) intention to raise an additional €300 million in senior secured notes from a syndicate of banks will have a limited effect on its deleveraging path in 2023 and 2024. We do not expect that the new debt issuance will affect the current recovery rating of '3'.

The proceeds from the proposed new issuance will remain in the balance sheet for potential bolt-on acquisitions or the payment of the deferred consideration that is due in July 2024 and linked to the Zyprexa acquisition from Eli Lilly. Therefore, we do not expect that the proposed new issuance will have any impact on our previous forecast of an S&P Global Ratings-adjusted debt to EBITDA of close to 5.5x in 2023 and about 5x in 2024.

Cheplapharm reported solid revenue in the first half of 2023. Year-on-year growth, which increased by 17% to €697.8 million, resulted from newly integrated investments in 2022 and the beginning of 2023 that led to higher volumes sold. This translated into a company-reported increase in EBITDA of 7.3% (€368.4 million), compared with the first half of 2022, even though personnel costs and other operating expenses increased the cost base. We believe the company should be able to meet our revenue and EBITDA expectations for 2023.

Cheplapharm successfully closed the acquisitions of Zyprexa in July 2023, which was in line with our expectations, Xeloda in May 2023, and Pulmicort in February 2023. We expect full contribution to the pipeline in 2024. Accounting for potential acquisitions, we project the company's free operating cash flow generation will remain strong at above €500 million in 2023 and 2024.

# Related Research

• CHEPLAPHARM Arzneimittel GmbH, July 26, 2023

#### Primary contact

#### **Ihsane Mesrar**

33-1-4075-2591 ihsane.mesrar @spglobal.com

#### Secondary contact

#### Nicolas Baudouin

33-14-420-6672 nicolas.baudouin @spglobal.com


### Analytical group contact

#### Industrial Ratings Europe Corporate\_Admin\_London

@spglobal.com

## Cheplapharm's Proposed New Issuance Will Not Affect Leverage Materially

•	Cheplapharm Proposed Acquisition Will Momentarily Stretch Leverage Above 5x, April 24,
	2023



Copyright © 2023 by Standard & Poor's Financial Services LLC. All rights reserved.

No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor's Financial Services LLC or its affiliates (collectively, S&P). The Content shall not be used for any unlawful or unauthorized purposes. S&P and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Parties be liable to any party for any direct, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P's opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P does not act as a fiduciary or an investment advisor except where registered as such. While S&P has obtained information from sources it believes to be reliable, S&P does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives. Rating-related publications may be published for a variety of reasons that are not necessarily dependent on action by rating committees, including, but not limited to, the publication of a periodic update on a credit rating and related analyses.

To the extent that regulatory authorities allow a rating agency to acknowledge in one jurisdiction a rating issued in another jurisdiction for certain regulatory purposes, S&P reserves the right to assign, withdraw or suspend such acknowledgment at any time and in its sole discretion. S&P Parties disclaim any duty whatsoever arising out of the assignment, withdrawal or suspension of an acknowledgment as well as any liability for any damage alleged to have been suffered on account thereof.

S&P keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P reserves the right to disseminate its opinions and analyses. S&P's public ratings and analyses are made available on its Web sites, www.spglobal.com/ratings (free of charge), and www.ratingsdirect.com (subscription), and may be distributed through other means, including via S&P publications and third-party redistributors. Additional information about our ratings fees is available at www.spglobal.com/usratingsfees.

STANDARD & POOR'S, S&P and RATINGSDIRECT are registered trademarks of Standard & Poor's Financial Services LLC.